[Season 2] Ep 3: Decoding GLP-1
US$ 26.68
tirzepatide patent owner expiry looms: Eli Lilly and Novo Nordisk strategise to defend their top obesity drugs in India Semaglutide & Tirzepatide Patent Considerations
Description
Retatrutide looks to have more average weight loss (24.2%) vs
Watch out for disclaimers, such as for research only, not for humans, or safe for humans but not approved. These disclaimers state that the product is unregulated or unsafe
Informed Consent Statement Patient consent was waived since it was retrieved from the public database, which contains de-identified data
The 20 mg/mL dosing chart shows that the 15 mg maximum dose requires only 75 units instead of 150
